person · Reporting owner

PFREUNDSCHUH PETER P.

Disclosed activity across 5 companies

Tapewire entity: 75195
SEC CIK: 0001585839

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Korro Bio, Inc.FREQ · Entity 6388	Chief Financial Officer	February 18, 2022	February 23, 2022
Voyager Therapeutics, Inc.VYGR · Entity 6271	Chief Financial Officer	February 21, 2024	February 22, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Korro Bio, Inc.

Report date February 18, 2022 · Filed February 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,927	Ending reported balance After 2022-02-22 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-02-18 · Sale · Disposed 1,404 · Balance 10,469 F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.79 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Row 2 · 2022-02-22 · Sale · Disposed 1,542 · Balance 8,927 F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.76. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.

F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.79 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.76. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Voyager Therapeutics, Inc.

Report date February 21, 2024 · Filed February 22, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	175,669	Reported balance After 2024-02-21 transaction · row 1 1 source row Row 1 · 2024-02-21 · Sale · Disposed 3,764 · Balance 175,669 F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.54, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.54, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, Class ASEC Table I · non-derivative	Direct	0	Reported balance After 2018-02-13 transaction · row 1 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 263 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2027-03-02	Direct	0	Reported balance After 2018-02-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-13 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").

F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

UroGen Pharma Ltd.

Report date October 15, 2020 · Filed October 16, 2020

Section 16 reporting ended · disclosed 2020-10-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,405	Ending reported balance After 2020-10-15 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2020-10-15 · Exercise / conversion · Acquired 4,917 · Balance 12,805 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2020-10-15 · Sale · Disposed 976 · Balance 11,829 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Row 3 · 2020-10-15 · Sale · Disposed 407 · Balance 11,422 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Row 4 · 2020-10-15 · Sale · Disposed 1,017 · Balance 10,405 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,667	Reported balance After 2020-10-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-15 · Exercise / conversion · Disposed 833 · Balance 1,667 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,082	Reported balance After 2020-10-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-15 · Exercise / conversion · Disposed 2,084 · Balance 2,082 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 5,000 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	4,000	Reported balance After 2020-10-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-15 · Exercise / conversion · Disposed 2,000 · Balance 4,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 5,000 ordinary shares. Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F4: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 5,000 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F5: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 5,000 ordinary shares. Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

Y-mAbs Therapeutics, Inc.

Report date September 16, 2025 · Filed September 18, 2025

Section 16 reporting ended · disclosed 2025-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-09-16 transaction · row 1 1 source row Row 1 · 2025-09-16 · Disposition to issuer · Disposed 77,800 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. F3: At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration").
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.47 · Expires 2034-07-12	Direct	Reported balance After 2025-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-09-16 · Disposition to issuer · Disposed 170,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F4: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16 · Expires 2035-01-17	Direct	Reported balance After 2025-09-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-09-16 · Disposition to issuer · Disposed 63,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F4: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-09-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-09-16 · Disposition to issuer · Disposed 15,900 · Balance 0 F5: Performance-Based RSUs ("PRSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU. F6: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-09-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-09-16 · Disposition to issuer · Disposed 15,900 · Balance 0 F5: Performance-Based RSUs ("PRSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU. F6: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU.

F3: At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration").

F4: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.

F5: Performance-Based RSUs ("PRSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU.

F6: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 31, 2020 Filed Feb 4, 2020 17:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Unit · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006212 · doc4.xml · derivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F3 · derivative.expiration_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document
January 31, 2020 Filed Feb 4, 2020 17:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock options (right to buy) · Derivative	15,000	$0.00 Strike: $29.41	$0.00	Disclosure SEC source: 0001209191-20-006212 · doc4.xml · derivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F1 · derivative.expiration_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:15 UTC	UroGen Pharma Ltd. URGN · Entity 4466	SaleOrdinary Shares	667	$29.28	$19,529.76	Disclosure SEC source: 0001209191-20-005215 · doc4.xml · nonDerivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document
January 26, 2020 Filed Jan 28, 2020 22:15 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units (RSUs) · Derivative	1,666	$0.00	$0.00	Disclosure SEC source: 0001209191-20-005215 · doc4.xml · derivative · entry 3 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Ordinary Shares · 1,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document
January 26, 2020 Filed Jan 28, 2020 22:15 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	1,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-005215 · doc4.xml · nonDerivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
November 20, 2019 Filed Nov 22, 2019 18:29 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	1,042	$0.00	$0.00	Disclosure SEC source: 0001209191-19-057753 · doc4.xml · derivative · entry 3 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,291 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document
November 20, 2019 Filed Nov 22, 2019 18:29 UTC	UroGen Pharma Ltd. URGN · Entity 4466	SaleOrdinary Shares	354	$28.41	$10,057.14	Disclosure SEC source: 0001209191-19-057753 · doc4.xml · nonDerivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,439 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document
November 20, 2019 Filed Nov 22, 2019 18:29 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	1,042	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-057753 · doc4.xml · nonDerivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
August 20, 2019 Filed Aug 22, 2019 17:31 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	4,167	$0.00	$0.00	Disclosure SEC source: 0001209191-19-047107 · doc4.xml · derivative · entry 3 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Ordinary Shares · 4,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document
August 20, 2019 Filed Aug 22, 2019 17:31 UTC	UroGen Pharma Ltd. URGN · Entity 4466	SaleOrdinary Shares	1,416	$33.07	$46,827.12	Disclosure SEC source: 0001209191-19-047107 · doc4.xml · nonDerivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,751 F2 · balance_after: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document
August 20, 2019 Filed Aug 22, 2019 17:31 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	4,167	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-047107 · doc4.xml · nonDerivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 26, 2019 Filed Jan 29, 2019 22:25 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Unit · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-005803 · doc4.xml · derivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document
January 26, 2019 Filed Jan 29, 2019 22:25 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantEmployee Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $42.50	$0.00	Disclosure SEC source: 0001209191-19-005803 · doc4.xml · derivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2029-01-26 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:47 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerStock Option (right to buy) · Derivative	150,000	$7.10 Strike: $10.90	$1,065,000.00	Disclosure SEC source: 0001171843-18-001102 · f4_pfreundschuh021318.xml · derivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document
February 13, 2018 Filed Feb 13, 2018 16:47 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	Disposition to issuerCommon Stock, Class A	263	$18.00	$4,734.00	Disclosure SEC source: 0001171843-18-001102 · f4_pfreundschuh021318.xml · nonDerivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). Read SEC document
December 31, 2017 Filed Jan 12, 2018 18:05 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	263	$9.10	$2,393.30	Disclosure SEC source: 0001171843-18-000353 · formfour.xml · nonDerivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263 F2 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F3 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document
September 30, 2017 Filed Jan 12, 2018 18:05 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantCommon Stock, Class A (ESPP)	131	$9.10	$1,192.10	Disclosure SEC source: 0001171843-18-000353 · formfour.xml · nonDerivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F3 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock. Read SEC document
March 20, 2017 Filed Mar 22, 2017 16:02 UTC	Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352	GrantEmployee Stock Option (right to buy) · Derivative	150,000	$0.00 Strike: $10.90	$0.00	Disclosure SEC source: 0001171843-17-001686 · f4_pfreundschuh032217.xml · derivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Class A Common Stock · 150,000 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option will vest over a four-year period, with 25% vesting on March 20, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.